Superworth

PTC Therapeutics profit margin PTCT

Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.

Net margin, 12 months
−9.2%
Operating margin, 12 months
12.8%
Net margin on a year earlier
−51.4 pts
Peer median
8.1%

Over the twelve months to Sep 30, 2026, PTC Therapeutics kept −9.2% of its revenue as net profit, with an operating margin of 12.8%.

Five years earlier its net margin was −92.4%.

The median for 10 large drugmakers of a similar size is 8.1%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202539.4%50.1%n/a
FY2024−45.0%−37.5%n/a
FY2023−66.8%−46.9%n/a
FY2022−80.0%−64.0%n/a
FY2021−97.3%−69.5%n/a
FY2020n/an/an/a
FY2019−82.0%−78.6%96.0%
FY2018−48.4%−43.7%95.2%
FY2017−40.6%−33.1%97.5%
FY2016n/an/a100.0%
FY2015n/an/an/a
FY2014n/an/an/a
FY2013n/an/an/a
FY2012−77.3%−79.0%n/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q3 FY26−9.2%−51.4 pts12.8%
Q2 FY26−3.8%−39.5 pts12.5%
Q1 FY26−22.6%−56.1 pts−7.1%
Q4 FY2539.4%+84.5 pts50.1%
Q3 FY2542.3%+92.6 pts43.6%
Q2 FY2535.6%+88.9 pts40.7%
Q1 FY2533.6%+96.0 pts40.2%
Q4 FY24−45.0%+21.8 pts−37.5%
Q3 FY24−50.3%+30.1 pts−14.9%
Q2 FY24−53.3%+22.2 pts−22.0%
Q1 FY24−62.4%+11.7 pts−39.6%
Q4 FY23−66.8%+13.2 pts−46.9%

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

Where PTC Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.